Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.59 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4236286 | 0.78 | HRH3 (0.51) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL13699322 | 0.77 | EPHX2 (0.43) | EPHX2 | |
| SCHEMBL4236560 | 0.77 | SLC6A2 (0.67) | CHRM2CHRM4CHRM1CHRM3EPHX2 | |
| SCHEMBL8437114 | 0.74 | ALDH1A1 (0.56) | EPHX2 | |
| SCHEMBL27917122 | 0.74 | CHRM2 (1.00) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL11755572 | 0.71 | PARP10 (0.71) | EPHX2 | |
| SCHEMBL27516126 | 0.71 | ALDH1A1 (0.49) | EPHX2 | |
| SCHEMBL16701853 | 0.70 | HRH3 (0.61) | EPHX2 | |
| SCHEMBL4236506 | 0.70 | ALDH1A1 (0.55) | EPHX2 | |
| SCHEMBL13699096 | 0.70 | ALDH1A1 (0.55) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | CHRM2 120/4885CHRM4 149/4885CHRM1 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.